Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Neoadjuvant chemoradiotherapy (CRT) followed by surgery has become the standard treatment
option for locally advanced esophageal squamous cell cancer (ESCC). However, only 20% to 40%
of patients can achieve pathologic complete response (pCR) after neoadjuvant CRT with
favorable prognosis and about 10% of patients have disease progression after
chemoradiotherapy. How to improve the the efficacy of neoadjuvant therapy is an important
clinical problem to be solved.
Immunotherapy targeting the PD-1/PD-L1 checkpoints has demonstrated promising activity in
advanced EC especially in ESCC. In Keynote181 study, for patients with metastatic esophageal
squamous cell carcinoma, regardless of PD-L1 expression, pembrolizumab significantly improved
overall survival compared with chemotherapy. However, the efficacy and safety of
immunotherapy therapy in surgery-based multidisciplinary treatment of local advanced
esophageal cancer still need a lot of clinical studies to further confirm.
The aim of this study was to evaluate the efficacy and safety of the neoadjuvant
chemoradiotherapy combined with perioperative toripalimab in patients with locally advanced
esophageal squamous cell cancer.